Your brain makes its own cannabis-like chemicals every day. THC borrows that system directly. CBD does something murkier. Here is what each one actually touches, and what it does not.
Part 17 of the Brain Chemistry series. New here? Start with Your Brain Is Not a Gas Tank, the short orientation that explains the four questions every article in this series answers.
What to know
- Your body makes two main endocannabinoids, anandamide and 2-AG. They are fats, made on the spot when a cell needs them, not stored in advance.
- These messengers often travel backward across a connection between two cells and tell the earlier cell to release less of its own signal.
- THC activates the same receptors your endocannabinoids use. CBD does not work that way. It touches several targets, and its full mechanism is still not settled.
- One purified prescription CBD product is approved for specific seizure disorders in patients 1 year and older. It has no psychiatric approval. Store-bought CBD is a different, unregulated product.
- No blood test, urine test, or gene panel can show your brain’s endocannabinoid level. Calming down after cannabis does not prove you were short on anything beforehand.
The short answer
Anandamide and 2-AG are your body’s own cannabis-like chemicals, called endocannabinoids. “Endo” means made inside the body. Unlike most brain chemicals, they are not packaged and stored ahead of time. A cell makes them when local activity calls for them, uses them right away, and breaks them down fast.
Their most common job is local feedback. A receiving cell makes an endocannabinoid and sends it backward to the cell that just signaled it. That backward-traveling messenger lands on a receptor called CB1 and tells the sending cell to release less of its own chemical next time. Depending on the circuit, that chemical being turned down might be glutamate, which excites, or GABA, which calms. Same feedback move, opposite results, depending on where it happens.
THC, the main intoxicating chemical in cannabis, activates CB1 directly. That is most of what makes cannabis feel the way it does. CBD, cannabidiol, is a different story. It is not a simple CB1 switch. It touches several targets, and researchers have not settled on one clean mechanism for it.
One purified CBD product has FDA approval, but only for specific seizure disorders in patients 1 year and older, not for anxiety, depression, or any other psychiatric condition.4 No FDA-approved psychiatric medicine works by directly correcting anandamide, 2-AG, or their receptors.12
More signaling from this system is not automatically better. CB1 receptors sit on many kinds of nerve endings, including ones that calm a circuit down and ones that rev it up. A single drug can quiet one pathway while accidentally freeing up another.
Think of it like a volume knob that only exists while your hand is on it. Most brain chemicals get made ahead of time and stored in tiny packets, ready to fire the moment a signal arrives. Anandamide and 2-AG skip that step. A nerve cell builds them out of its own membrane fat right when it needs them, uses them within seconds, and then enzymes tear them apart. There is no reserve tank.
The direction is also unusual. Most signals travel one way, from a sending cell to a receiving one. Endocannabinoids often run the opposite direction. The receiving cell makes the message and sends it backward, telling the cell that just spoke to speak more quietly next time. Scientists call this retrograde signaling, and it is a well-established way that brain circuits fine-tune themselves moment to moment.3
Two enzymes end most of this signaling. FAAH breaks down anandamide. MAGL breaks down most of the brain’s 2-AG. A few other enzymes handle the rest. Because two separate systems make and clear these chemicals, a drug built to change one does not automatically change the other the same way.
THC and CBD are not the same kind of chemical
THC is a direct match for the system described above. It activates CB1 and CB2 receptors almost the way your own endocannabinoids do, and that direct activation explains most of cannabis’s intoxicating effects, including changes in perception, memory, coordination, appetite, and anxiety.
CBD is genuinely different. It is not simply “THC without the high.” It does not act as a straightforward CB1 or CB2 switch. Researchers have proposed several other targets for it, and its complete mechanism is still not settled. This matters because people sometimes assume CBD is a gentler dial on the same knob THC turns. It is closer to a different instrument entirely.
This difference also explains why the FDA drew such a narrow line around CBD. One purified, standardized CBD product is approved, and only for specific severe seizure disorders in patients 1 year of age and older. It does not carry a psychiatric approval.4 A bottle of CBD oil from a shop shelf is not the same product. Store CBD content varies from bottle to bottle, and some products contain THC even when the label does not say so. A store product is not automatically equivalent to the studied, standardized prescription version.
The medication-to-signal map
These are the clinically meaningful examples, not every compound ever studied.
| Medicine | What it does directly, used for, and main tradeoffs |
|---|---|
| Dronabinol capsules | What it does directly: Oral synthetic THC that activates CB1 and CB2, mainly through CB1 in the brain. Used for: AIDS-related appetite loss; chemo-related nausea and vomiting when usual anti-nausea treatment has not worked well enough. Main tradeoffs: Mood and perception changes, impaired coordination, heart-rate or blood-pressure effects, seizures, and misuse risk. Schedule III, no psychiatric approval 5. |
| Nabilone (Cesamet) capsules | What it does directly: Oral synthetic cannabinoid acting mainly through CB1. Used for: Chemo-related nausea and vomiting when usual anti-nausea treatment has not worked well enough. Main tradeoffs: Drowsiness, dizziness, impaired thinking, mood or psychotic-like effects, low blood pressure, and misuse risk. Schedule II. Not established as safe and effective under age 18, no psychiatric approval 6. |
| Prescription CBD (Epidiolex) | What it does directly: Acts at several targets, not a simple CB1 or CB2 switch. Used for: Specific severe seizure disorders in patients 1 year and older. Main tradeoffs: Liver injury, sedation, drug interactions, and required monitoring. No psychiatric approval 4. |
| Consumer CBD products | What it does directly: Variable, multi-target, and unproven. Used for: Not an approved treatment for anything psychiatric. Main tradeoffs: Content varies bottle to bottle, some contain undisclosed THC, and liver and interaction risks exist without the oversight a prescription product has. |
| THC-dominant cannabis products | What it does directly: Direct CB1 activation, plus whatever else the specific product contains. Used for: Allowed under some state laws; not FDA-approved to treat any disease. Main tradeoffs: Impairment, panic, and psychosis risk in some people, along with pregnancy and adolescent-brain concerns and the possibility of cannabis use disorder. |
| Rimonabant (historical) | What it does directly: Blocked CB1 below its normal baseline activity. Used for: Was developed for weight loss. Main tradeoffs: An FDA advisory committee did not recommend U.S. approval in 2007 because of depression, anxiety, and suicidality concerns. European approval was withdrawn in 2009 7 8. |
Rimonabant is worth sitting with. It worked exactly as designed at the receptor level and reduced appetite, but broadly turning down CB1 signaling across the whole brain carried a serious psychiatric cost. It is a clear lesson that hitting the right target is not the same as producing a safe or useful medicine.
A related lesson comes from a very different compound. BIA 10-2474, an experimental FAAH inhibitor, caused severe neurologic injury and one death in an early trial, thought to involve effects outside its intended target.9 And a 2025 trial of the FAAH inhibitor JNJ-42165279, added to internet-delivered therapy for PTSD, did raise anandamide the way it was designed to over 12 weeks. Symptoms did not improve any more than with therapy and placebo alone.1 Reaching the target and helping the person are two separate questions, and a drug can succeed at one without succeeding at the other. A broader 2026 review of randomized psychiatric cannabinoid trials found the current evidence does not support routine cannabinoid treatment for most mental health conditions.10
Meet the receptor family
| Target | Basic action, where it matters, and why you might care |
|---|---|
| CB1 | Basic action: Mostly sits on the sending side of a connection and lowers the next release of a chemical. Where it matters: Cortex, hippocampus, memory and movement circuits, appetite and reward pathways. Why you might care: This is THC’s main target and where intoxication, memory changes, and appetite effects come from. |
| CB2 | Basic action: Changes immune and cell-state signaling. Where it matters: Immune tissue, some brain cells including microglia. Why you might care: Studied for inflammation and pain, but no routine selective CB2 psychiatric medicine exists. |
| FAAH | Basic action: Enzyme that breaks down anandamide. Where it matters: Throughout brain and body. Why you might care: Slowing this enzyme raises anandamide without directly switching on CB1, but that has not yet produced a working psychiatric treatment. |
| MAGL | Basic action: Enzyme that breaks down most brain 2-AG. Where it matters: Nerve endings and glial cells. Why you might care: A different cleanup route than FAAH, which is why a drug built for one enzyme does not automatically affect the other messenger. |
| Other targets, including TRPV1 | Basic action: Various receptor and channel actions that differ by chemical and exposure. Where it matters: Sensory, brain, and immune tissue. Why you might care: Part of why anandamide and especially CBD cannot be reduced to a simple CB1 story. |
Cannabis, psychosis, pregnancy, and the developing brain
Cannabis is not a universal calming agent. Acute THC relaxes one person and triggers panic, paranoia, or psychotic-like symptoms in another, often within the same afternoon depending on dose, product, and setting.
At a group level, more frequent cannabis use, especially with higher-THC products, is linked to a higher probability of psychotic outcomes. That is a statement about groups, reviewed by the National Academies, not a diagnosis for any one person, and other explanations, including shared risk factors, are part of that picture.11
Two groups deserve their own conversation with a clinician rather than general reassurance: people who are pregnant or breastfeeding, and adolescents, whose brains are still developing key circuits that this system helps shape. The CDC has summarized specific risks for teens.12 If cannabis is part of your life or your family’s life in either of these situations, that is a conversation for a clinician, not a symptom checklist.
Can it be measured?
Not the way people hope. Research PET scans can estimate how many CB1 receptors are available in a living brain, under specific assumptions built into the tracer. That is a research tool. It cannot tell a clinician how much anandamide “should” be there or whether a person needs more.
Blood levels of anandamide or 2-AG reflect what is happening outside the brain, shaped heavily by the blood draw itself, food, stress, and activity. Urine drug tests detect THC metabolites, which can confirm past exposure within the limits of the test, but they do not measure CB1 activity, current impairment, or why someone used cannabis in the first place.
Genetic tests can find variants in genes tied to this system, but a variant does not report what your receptors are doing right now. No commercial blood, urine, saliva, hair, or genetic panel has been validated to pick a psychiatric medicine based on someone’s brain endocannabinoid level.
Which symptoms need a call, and which need urgent help
Track and mention at your next visit: mild, short-lived drowsiness, dry mouth, appetite change, or dizziness. Note the product, timing, and what you were doing, and do not drive or do anything hazardous while impaired.
Call the prescriber or pharmacist promptly: a mood change that will not settle, repeated panic or paranoia, excessive sedation, worsening function, a suspected drug interaction, or, with prescription CBD, yellow skin or eyes, dark urine, or other signs that could point to liver trouble.
Call Poison Control at 1-800-222-1222 for a possible ingestion or poisoning, including a child who has eaten a THC product. Do not wait for symptoms to appear in a young child.
Call 911 now for collapse, seizure, trouble breathing, inability to wake someone, or severe confusion paired with unsafe behavior. For a suicidal or mental health crisis, call or text 988. If danger is immediate, call 911.
What to ask your prescriber
These are conversation starters, not instructions.
- Which symptom or function is this treatment meant to change?
- Does it act directly on CB1, CB2, FAAH, or another target, or is the connection more indirect?
- Is this an FDA-approved use, an off-label use, or still investigational?
- What early effects might settle on their own, and which should prompt a call?
- Could this interact with CBD, THC, alcohol, sedatives, or antiseizure medicines I already take?
- Does this specific product need liver, mood, or other monitoring?
- What should I do if I miss a dose?
- Could stopping suddenly cause withdrawal, rebound symptoms, or a return of the original problem?
Bottom line
Feeling calmer after cannabis, or feeling worse, does not prove your brain was short on or flooded with anything beforehand. Your endocannabinoid system runs on messengers made in the moment, not stored in reserve, and it hands most of the work to one receptor, CB1, sitting in a dozen different circuits with a dozen different jobs. THC borrows that system directly. CBD works through a murkier, still-unsettled set of targets, and only one purified, standardized version of it has any FDA approval at all, for seizures, not mood. Bring the exact product, the exact effect, and your full medication list to a prescriber or pharmacist rather than reading meaning into how a substance made you feel. For the wider idea that no single brain chemical works alone, see Your Brain Is Not a Gas Tank.
Frequently asked questions
If cannabis calms me down, does that mean my endocannabinoids were low?
No. A response after exposure shows an effect of the exposure. It does not reveal what your brain lacked beforehand.
Is CBD an approved anxiety medicine?
No. The one FDA-approved purified CBD product treats specific seizure disorders in patients 1 year and older. It has no psychiatric approval.4 Store CBD products are not interchangeable with it.
Can a blood or urine test show my brain’s endocannabinoid level?
No. Blood fats and urine THC metabolites answer narrow, different questions. Neither measures signaling happening at a living connection between two brain cells.
Why does THC calm one person and make another anxious?
CB1 receptors sit across many different circuits. Product strength, route, tolerance, age, setting, sleep, other substances, and personal vulnerability all shape the result.
If a FAAH inhibitor raises anandamide, should symptoms improve right away?
Not necessarily. A 2025 PTSD trial showed anandamide rising as designed, but symptoms did not improve more than with therapy plus placebo.1 Hitting the target and improving symptoms are separate outcomes.
Does a side effect mean a cannabinoid product is working?
No. Impairment, sedation, panic, or nausea can all be adverse effects on their own. They do not prove a corrected imbalance.
Why does stopping regular cannabis use feel hard for some people?
Repeated CB1 activation can lead to adaptation. When exposure drops, withdrawal symptoms such as irritability, sleep trouble, or craving can follow. That is a separate question from addiction, which involves loss of control and continued use despite harm.
Related reading on NP FADY
- Your Brain Is Not a Gas Tank (start here)
- Your Body Makes Its Own Opioids
- Cannabis and Mental Health
- CBD for Anxiety and Sleep: What We Know, What We Don’t
- Drug Interactions to Know: Antidepressants, Alcohol, CBD, and More
References
1. FAAH inhibitor JNJ-42165279 PTSD trial report. PMC. Accessed August 31, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC12339700/
2. FDA regulation of cannabis and cannabis-derived products, including CBD. FDA. Accessed August 31, 2026. https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd
3. Castillo and colleagues, review of retrograde synaptic signaling. PMC. Accessed August 31, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC3517813/
4. Cannabidiol (Epidiolex) prescribing information. DailyMed. Accessed August 31, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bf27097-4870-43fb-94f0-f3d0871d1eec
5. Dronabinol capsules prescribing information. DailyMed. Accessed August 31, 2026. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=adb1801c-0fb5-4e16-b969-1db91230e0b9
6. Nabilone (Cesamet) capsules prescribing information. DailyMed. Accessed August 31, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83c7ac15-ece9-47de-b83c-d575544fa449
7. Rimonabant regulatory history. FDA. Accessed August 31, 2026. https://www.fda.gov/drugs/frequently-asked-questions-popular-topics/questions-and-answers-about-fdas-initiative-against-contaminated-weight-loss-products
8. Acomplia (rimonabant) European public assessment report. EMA. Accessed August 31, 2026. https://www.ema.europa.eu/en/medicines/human/EPAR/acomplia
9. BIA 10-2474 molecular investigation. PMC. Accessed August 31, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC5641481/
10. 2026 systematic review of randomized psychiatric cannabinoid trials. PMID: 41856154
11. National Academies, The Health Effects of Cannabis and Cannabinoids, evidence review. NCBI Bookshelf. Accessed August 31, 2026. https://www.ncbi.nlm.nih.gov/books/NBK425748/
12. Cannabis and teens. CDC. Accessed August 31, 2026. https://www.cdc.gov/cannabis/health-effects/cannabis-and-teens.html
This article is general education. It is not a diagnosis or a treatment plan. Do not start, stop, or change a medicine, supplement, or cannabis product because of something you read here. Review every prescription, supplement, and substance with your prescriber or pharmacist.
If you or someone you know is in crisis
- Call 911 or go to your nearest emergency room for any life-threatening emergency.
- 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.
- Crisis Text Line — text HOME to 741741.
- The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
- National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
- National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
- Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
- San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
- Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
- California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
- NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.